UNC569|cas:1350547-65-7|西域试剂

UNC569,98.64%

产品编号：Bellancom-117596| CAS NO：1350547-65-7| 分子式：C₂₂H₂₉FN₆| 分子量：396.50

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117596	￥1100.00	杭州北京（现货）
Bellancom-117596	￥1800.00	杭州北京（现货）
Bellancom-117596	￥4000.00	杭州北京（现货）
Bellancom-117596	￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

UNC569

产品介绍

UNC569 是一种有效、可逆、ATP 竞争性且具有口服活性的 Mer 激酶抑制剂，IC₅₀ 为 2.9 nM，K_i 为 4.3 nM。UNC569 还抑制 Axl 和 Tyro3，IC₅₀ 分别为 37 nM 和 48 nM。UNC569 可用于急性淋巴细胞白血病 (ALL) 和非典型畸胎瘤/横纹肌瘤的研究。

生物活性

UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

体外研究

UNC569 (24 hours) induces apoptosis in ALL cell lines, and increases the levels of cleaved Caspase 3 and cleaved PARP.
UNC569 (1 µM; 1.5 hours) treatment effectively inhibit the activation of Mer and downstream signaling, including the PI3K/AKT and MAPK/ERK pathways.
UNC569 (1 hour) inhibits Mer phosphorylation levels with IC50 values of 141 nM and 193 nM in human B-ALL (acute lymphoblastic leukemia) 697 and Jurkat cell lines, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	697 and Jurkat cells
Concentration:	0.4 µM, 0.8 µM, 1 µM, 1.2 µM, 1.4 µM, 1.6 µM, 1.8 µM, 2 µM
Incubation Time:	24 hours
Result:	Induced apoptosis in ALL cell lines.

Western Blot Analysis

Cell Line:	697 and Jurkat cells
Concentration:	1 µM
Incubation Time:	1.5 hours
Result:	Inhibited Mer activation and downstream signaling through ERK1/2 and AKT.

体内研究
(In Vivo)

The in vivo pharmacokinetic properties of UNC569 (3 mg/kg) are also assessed in mice via both intravenous (IV) and oral (PO) administration. UNC569 has low systemic clearance (19.5 mL/min/kg), high volume of distribution (V_ss of 5.83 L/kg), and good oral bioavailability (57%).
Leukemic zebrafish are treated continuously for 2 weeks by immersion in 4 µM UNC569. the result shows that UNC569 induces more than 50% reduction in tumor burden compared with vehicle- and mock-treated fish.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 31.25 mg/mL (78.81 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5221 mL	12.6103 mL	25.2207 mL
5 mM	0.5044 mL	2.5221 mL	5.0441 mL
10 mM	0.2522 mL	1.2610 mL	2.5221 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.31 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明